“Dr. Goliber’s early-stage scientific and program management expertise and extensive practical experience are a perfect fit for our early-stage biopharma clients.”
ROCHELLE, VIRGINIA (PRWEB) March 02, 2016
NDA Partners Chairman Carl Peck, MD, announced today that Philip Goliber, PhD, has been appointed a Partner in the company. Dr. Goliber has worked with NDA Partners as an Expert Consultant in early-stage drug development since September 2013. Prior to that, he was Vice President, Strategy and Portfolio, and Vice President Pharmaceutical and Analytical Sciences, at UCB Pharma, SA. In his new role as a Partner, Dr. Goliber will provide leadership in early-stage development efforts for the company’s biopharma clients, guidance on CMC and regulatory strategy, and program management oversight of virtual product development teams.
Dr. Goliber’s technical expertise covers both R&D and operations. His management responsibilities have included DMPK, API development, pharmaceutics, and analytics and have encompassed both small molecule drugs and biologics. He has participated in the planning, logistics and execution of dozens of drug development programs and has significant experience in international pharmaceutical industry, including living in and working in Europe, establishing relationships with partners in India and China, and working with emerging market countries.
“Dr. Goliber’s early-stage scientific and program management expertise and extensive practical experience are a perfect fit for our early-stage biopharma clients,” said Dr. Peck. “We have worked with Dr. Goliber for many years and are very pleased that he has accepted our invitation to become a Partner in the firm.”
Dr. Goliber earned both an MS and PhD in chemistry from the University of Connecticut. In addition to UCB, his career has included positions with Penwest Pharmaceuticals, Warner Lambert, Boehringer Ingelheim Pharmaceuticals, and UCB Pharma.
About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Expert Consultants at NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 60 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.
Earle Martin, Chief Executive Officer